Hikma Gets $535m Off BI's Roxane Over Rebate Discrepancy
This article was originally published in Scrip
"A very good deal that just got a little sweeter," is how Hikma CEO Said Darwazah described the $535m purchase price reduction of Roxane Laboratories Inc. from Boehringer Ingelheim. The discount was result of "new information" from BI in relation to Roxane's financial performance in 2015, specifically higher than expected rebates offered by Roxane.
Register for our free email digests: